Graft-versus-host disease (GVHD) is the single most important complication of allogeneic stem cell transplantation (SCT), and it results in the majority of treatmentrelated mortality.
1,2 Acute GVHD is a progressive systemic illness with immunosuppression, cachexia and specific target organ damage to skin, liver and intestines. 3 Although the effector mechanisms of GVHD have not been fully clarified, effects of cytotoxic T lymphocytes (CTL), natural killer (NK) cells and macrophages -by means of inflammatory cytokines and cytotoxic effector moleculeshave been considered as the main mechanism. 4 CTL are important effector cells in GVHD, 5 and they seem to exert their cytolytic activity through two lytic pathways: Fas/Fas ligand (FasL) and perforin/granzyme B. 6, 7 Interaction of FasL (expressed on the CTL cell surface) with the Fas receptor (on the target cell membrane) results in the initiation of the Fas cell death pathway. 8 The perforin/granzyme B pathway consists of the exocytosis of lytic granules, resulting in the release of perforin and granzyme B which leads to apoptosis-induced cell death. 9 It has also been suggested that the expression of tumor necrosis factor (TNF) may contribute to CTL cytotoxicity. 10 Several studies have also demonstrated the importance of the FasL and perforin pathways, as well as the TNF-a expression (or secretion) for the development of acute GVHD. [11] [12] [13] [14] [15] [16] However, FasL, granzyme B, perforin and TNF-a gene expression in acute GVHD has not been further evaluated in stem cell transplanted patients, and its clinical significance remains to be elucidated in humans.
Current procedures in diagnosing GVHD depend upon clinical judgments and histopathological examinations of biopsies. 17 These procedures are painful, associated with risk of hemorrhages, and do not always easily distinguish between incipient acute GVHD and other immunological events. 18 Therefore, the development of a noninvasive diagnostic test to provide insights into the mechanisms of GVHD would be of considerable value. The overall goal of this pilot study was to utilize the competitive reverse transcription (RT)-PCR as a sensitive approach to evaluating the pattern of immune activation of gene expression in acute GVHD and to test the reliability of gene expression analysis of peripheral blood as a diagnostic tool of acute GVHD. The study focused on the expression of granzyme B, perforin, FasL and TNF-a since these genes seem to be the major effector mechanisms involved in acute GVHD. Besides the gene expression of these effector genes, the associated protein production may also be associated with acute GVHD. 16, [19] [20] [21] Therefore, the plasma levels of granzyme B, sFasL and TNF-a in SCT recipients were also examined.
Materials and methods

Patients
Eight patients who underwent allogeneic SCT between October 2000 and April 2001 at the Center for Allogeneic Stem Cell Transplantation at Huddinge Hospital were included in this study. Three patients received stem cells from a human leukocyte antigen (HLA) identical sibling; five patients received cells from matched unrelated donors (MUD). The cell source was mobilized peripheral blood stem cells (n ¼ 5) or bone marrow (n ¼ 3). 22 Underlying diseases were chronic myeloid leukemia (n ¼ 3), acute myeloid leukemia (n ¼ 4) and aplastic anemia (n ¼ 1). Conditioning therapy consisted of a combination of cyclophosphamide (Cy) 120 mg/kg and busulfan (Bu) 16 mg/kg (n ¼ 5), or a combination of fractionated total body irradiation (fTBI) 4 Â 3 Gy and Cy (n ¼ 3). 23 Recipients of unrelated marrow were treated with thymoglobulin (IMTIX-Sangstst, Lyon, France) 6 mg/kg, prior to transplantation. 24 GVHD prophylaxis consisted of a combination of cyclosporine A (CsA) and methotrexate (MTX). 25 As part of the conditioning, patients with unrelated donors were given 2 mg/kg of antithymocyte globulin (ATG) per day, for 2 days. 26 Acute GVHD was diagnosed according to clinical and histopathological criteria. 17 Treatment started at the first sign of acute GVHD either with 6-methylprednisolone i.v., beginning with 2 mg/kg/day, or an equivalent dose of oral prednisolone, which was tapered off after an initial response. Table 1 summarizes patient characteristics.
Details regarding the transplantation and supportive care have been published elsewhere. 27, 28 The ethics committee at Karolinska Institute, Huddinge Hospital (339/00), approved this study.
Specimens
Peripheral blood samples were collected from patients on day 14, day 21, day 28, 6 weeks, 8 weeks and 3 months post-SCT. In total, 52 peripheral blood samples were analyzed for gene expression by granzyme B, perforin, FasL and TNF-a; 32 plasma samples were analyzed for protein concentrations of granzyme B, sFasL and TNF-a. All plasma samples were stored at À201C until further use.
RNA extraction and reverse transcription
RNA was isolated from peripheral blood buffy coats obtained by centrifugation (400 g for 10 min). A volume of 1 ml of the buffy coat was transferred to 6 ml of red cell lysis buffer from the QIAAMP RNA blood Mini-Kit (QIAGEN, Hilden, Germany). Total RNA was extracted from the cell lysate according to the manufacturer's instructions. RNA was eluted with 60 ml of RNase-free water, which was supplied with the kit.
Complementary DNA was synthesized in a total volume of 100 ml, containing 60 ml RNA, 1 Â first-strand buffer (supplied with RT), random hexamer oligonucleotide primer (105 mg/ml) (Pharmacia Biotech, Uppsala, Sweden), dNTP (1 mM of each) (Pharmacia Biotech, Uppsala, Sweden), DTT (1 mM, supplied with RT), RNasin (0.5 U/ ml) (Promega, Madison, WI, USA) and M-MLV RT (4.8 U/ml) (Invitrogen, Paisly, Scotland), at 371C for 1.5 h. The reaction was terminated at 671C for 15 min, and cDNA was stored at À201C until further analysis.
Quantification of gene expression by competitive template RT-PCR
The expression of granzyme B, perforin, FasL and TNF-a genes in peripheral blood samples was analyzed using a quantitative RT-PCR method. Competitor plasmids, containing modified copies of the gene of interest and the housekeeping gene glucose-6-phosphate-dehydrogenase (G6PD), were constructed ( Figure 1 ) to enable the quantification of gene expression. Quantification was performed by parallel PCR amplification of a series of dilutions of competitor plasmid -diluted in steps of halflog in magnitude (from 10 to 10 7 ) -and a constant amount of cDNA derived from blood samples. Competitor plasmid and cDNA both contained the same primer sites, which enabled sense and antisense oligonucleotides to proportionally amplify the two targets in accordance with their relative initial abundance. Because of the size difference between wild-type genes and the modified gene in competitor plasmids, the PCR products could be separated by agarose gel electrophoreses. The gels were stained with ethidium bromide and viewed in UV light. A semiquantitative estimation of gene expression was used and the band intensity of the gene of interest was compared to the band (5) UPN, unique patient number; CML, chronic myeloid leukemia; SAA, severe aplastic anemia; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; R, recipient; M, male; F, female; Sib, sibling; MUD, matched unrelated donor; PBSC, peripheral blood stem cell; BM, bone marrow; Bu, busulfan; fTBI, fractionated total body irradiation; Cy, cyclophosphamide; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; MTX, methotrexate; CsA, cyclosporineA; aGVHD, acute graft-versus-host disease; SCT, stem cell transplantation; A&W, alive and well; V, dead.
Immune transcript levels after allogeneic SCT M Jaksch et al from the competitor plasmid. The number of unknown cDNA copies of a certain gene was made apparent by the band intensities on the agarose gel. When the intensity of the two bands were equal, the amount of product was the same as the competitor. However, since the amplified product from the competitor plasmid was shorter than the product from the wild-type cDNA, the amplification of the gene in the competitor would occur more frequently. Therefore, a correction for size difference was made. Amplification of the housekeeping gene G6PD verified successful RNA isolation and reverse transcription, as well as the relative amount of RNA in every sample. Results were calculated as the ratio of the amount of detected gene transcript divided by the amount of detected G6PD in the same sample. Contaminating genomic DNA could easily be identified by size differences, because all oligonucleotides were targeted to separate exons of the gene of interest.
PCR conditions
cDNA (2.5 ml) and competitor plasmid (2.5 ml) were used in a 25 ml PCR reaction containing 1 Â PCR buffer (1.5 mM MgCl, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.001% w/v gelatine), dNTP (200 mM of each) (Perkin Elmer, Branchburg, CA, USA), glycerol (5%), cresol red (100 ng/ml), AmpliTaq polymerase (0.03 U/ml) (Perkin Elmer, Branchburg, CA, USA) and specific primers (0.5 mM each of sense and antisense).
The following amplification parameters were used to detect granzyme B, perforin and TNF-a: after an initial 4-min hot-start/denaturation step at 941C, 35 PCR amplification cycles were carried out in a PTC 200 thermal cycler (MJ Research, Watertown, CA, USA). The first 10 cycles were performed in a two-segment step: 941C for 30 s and 661C for one 1 min. The following 25 cycles were performed in a three-segment step: 941C for 15 s; 631C for 50 s; and 721C for 30 s. The following PCR program was used to detect FasL: after an initial 4-min hot-start/denaturation step at 941C, 40 PCR amplification cycles were carried out. The first 10 cycles were performed in a two-segment step: 941C for 30 s and 611C for 1 min. These were followed by 30 cycles performed in a three-segment step: 941C for 15 s; 591C for 50 s; and 721C for 30 s. Figure 1 shows the oligonucleotide sequences used in this study. All oligonucleotides were synthesized commercially (CyberGene, Huddinge, Sweden).
Protein analysis
For the quantitative determination of plasma concentrations of granzyme B, sFasL and TNF-a, commercially available ELISA kits were used and assayed according to 
Results
Patients
Six out of eight patients included in the study are alive; one patient died due to encephalitis (unique patient number (UPN) 834); and one died due to acute GVHD (UPN 803). Acute GVHD was diagnosed in five out of eight patients after SCT: one patient developed grade I acute GVHD; two patients developed grade II; one patient developed grade III and one patient was diagnosed with grade IV acute GVHD ( Table 1 ). The median time for developing acute GVHD was 16 days (range of 12-27 days) after SCT. After SCT, four patients (UPN 803, 806, 814 and 815) developed a bacterial septicemia on day 52, day 3, day 6 and day 10, respectively. One (UPN 814) developed pericarditis on day 67 after SCT. UPN 831 developed hemolysis on day 24 after SCT.
mRNA levels in patients with acute GVHD Grades I-IV of acute GVHD were diagnosed in five patients (UPN 802, 803, 806, 815 and 834) ( Table 1 ). In four of the patients, the gene expression levels of granzyme B, perforin and FasL were increased, compared to blood samples taken before acute GVHD was diagnosed. Median gene expression levels are summarized in Table 2 .
Patient UPN 834, developed a skin rash and was diagnosed with grade I acute GVHD on day 22 after SCT. Two days before the diagnosis, the patient showed elevated levels of granzyme B and perforin (100 Â and 32 Â , respectively), compared to a blood sample taken 6 days earlier (Figure 2 ). FasL gene expression was already at a high level 6 days before the onset of acute GVHD. Furthermore, only day after the initiation of prednisolone (2 mg/kg/day), the magnitude of the gene expressions of granzyme B, perforin and FasL declined. However, when the cortisone dose was lowered (prednisolone 1 mg/kg/day), there was an upregulation of expression of perforin and FasL genes. This change in mRNA levels led to the diagnosis of intestinal grade III acute GVHD on day 72 after SCT. In the sample from day 65 (the last sample before diagnosis), perforin and FasL had both increased 10 Â compared to the sample taken 10 days earlier. Granzyme B levels were unchanged after the initial decrease.
In UPN 806, grade I acute GVHD was diagnosed on day 13 after SCT; no blood sample was available before the diagnosis. However, despite cortisone therapy, there was an increase in mRNA levels of granzyme B, perforin and FasL, prior to day 24 when grade II acute GVHD was diagnosed in the liver (Figure 3 ). Four days before the diagnosis, the levels were increased 10 Â for granzyme B, 32 Â for perforin and 320 Â for FasL. Three days after the initiation of intensified therapy, the expression of the three genes declined by three-fold.
In UPN 803, grade I acute GVHD was diagnosed on day 12; no blood sample was available before the diagnosis. However, on day 31 after SCT, levels of granzyme B, perforin and FasL were increased (3 Â , 10 Â and 32 Â , respectively), even though steroid treatment had been initiated. Intestinal grade III acute GVHD was diagnosed on day 31. An upregulation of granzyme B, perforin and Table 2 Gene expression levels in patients with or without acute GVHD Immune transcript levels after allogeneic SCT M Jaksch et al FasL was also detected at the time of a bacterial septicemia, day 52 after SCT. In UPN 802, who was diagnosed with grade II acute GVHD in the liver on day 27 after SCT, an increase in gene expression levels was detected 5 days before diagnosis. Compared to the previous blood samples, granzyme B, perforin and FasL were increased by 10 Â , 3 Â and 3 Â , respectively. One day after the initiation of GVHD therapy, the granzyme B expression levels had declined, however, the expression levels of perforin and FasL were still unchanged. UPN 802 showed the highest level of FasL at the time of engraftment (white blood cell count 40.2 Â 10 9 / l) on day 15 after SCT. However, gene expression decreased spontaneously until mRNA levels increased in connection with grade II acute GVHD.
UPN 815 was diagnosed with hepatic grade I acute GVHD on day 16. The patient developed a bacterial septicemia on day 10 after SCT. Immune transcript levels were already at a high level at the onset of the septicemia, which made it difficult to evaluate the gene expression levels. Increased immune transcript levels were detected at the time of acute GVHD, however, it was not clear whether or not the increase was because of an evolving acute GVHD or the septicemia. With this patient, steroids were also tapered off rapidly and withdrawn 2 weeks after therapy was initiated.
The clinical severity of acute GVHD did not correlate with the expression levels of the gene transcripts. We did not observe any significant differences in the levels between grade I and grades II-IV acute GVHD. Furthermore, this study indicated that TNF-a mRNA expression levels showed no definite correlation with acute GVHD.
mRNA levels in patients without acute GVHD
In three patients (UPN 814, 826 and 831), no acute GVHD was diagnosed. However, these patients showed increased mRNA levels for granzyme B, perforin, FasL and TNF-a at various times after SCT. The median levels are summarized in Table 2 .
In UPN 814, FasL gene expression increased 1000 Â because of a pericarditis. However, after cortisone treatment, gene expression levels decreased to the original levels. In UPN 831, with a blood group incompatible donor, gene expression levels increased 3 Â for granzyme B, 10 Â for perforin and 10 Â for FasL from day 14 to day 24. Hemolysis was diagnosed on day 24 after SCT; when the hemolysis spontaneously declined, the levels decreased to the original levels. The third patient, UPN 826, showed an increase in granzyme B (3 Â ) and FasL (30 Â ) for unknown reasons after the patient was discharged from the hospital.
Gene expression and plasma concentrations
In five out of eight patients, there was a close correlation (0.58oro0.99) between the granzyme B protein levels and the expression of the corresponding gene. No correlation between granzyme B protein levels and gene expression was observed in one patient.
For sFasL, there was a correlation (0.63oro0.74) between gene expression and protein levels in three out of eight patients. In two of eight patients, there was no correlation between mRNA and protein levels. Median protein levels for granzyme B and sFasL are summarized in Table 3 .
In six out of eight patients plasma levels of TNF-a were under the level of sensitivity for the assay used. Plasma samples from the remaining patients were evaluated. However, there was no correlation between the TNF-a protein levels and mRNA levels from the corresponding gene. Even though one of these patients (UPN 802) developed acute GVHD both patients showed declining TNF-a protein levels after SCT.
In all cases of correlation, the increases in protein levels were delayed compared to the up-regulation of the corresponding gene. However, in order to evaluate the delay, more frequent monitoring is required. Immune transcript levels after allogeneic SCT M Jaksch et al Discussion GVHD is a major life-threatening complication of allogeneic SCT. Once severe acute GVHD has developed, it is very difficult to treat. 29 Therefore, it is important to diagnose, monitor and treat this disease both rapidly and precisely.
Donor T cells are crucial for its development, 5 and the results from a variety of studies have led to the definition of three important effector pathways for the cytotoxic killing: Fas/FasL; perforin/granzyme B and the release of cytokines such as TNF-a. 6, 7, 10 The importance of these pathways in the development of acute GVHD has been demonstrated in several animal studies.
11-14 Using a FasL-deficient (gld) mice model, it has been shown that there is a close relation between the Fas/ FasL system and acute GVHD, especially hepatic and cutaneous acute GVHD.
11, 14 Hattori et al 14 also demonstrated that TNF-a predominantly mediated intestinal and cutaneous acute GVHD. A few studies in humans have shown that renal allograft rejection is associated with the expression of a specific subset of immune activation genes. Kidney rejection was associated with increased gene expression levels of granzyme B, perforin and FasL. 30 In a study by Li et al, 31 acute rejection of renal allografts could be diagnosed accurately and noninvasively by the quantification of perforin and granzyme B mRNA in urine. Since acute GVHD may use the same mechanisms as allograft rejection, monitoring the expressions of granzyme B, perforin, FasL and TNF-a genes may work as a diagnostic method to predict and monitor acute GVHD in SCT patients. Presently, only a few groups have analyzed immune transcript levels in humans after SCT. 15, 16 In agreement with our hypothesis that acute GVHD is associated with the expression of a specific subset of immune activation genes, we determined that acute GVHD might be associated with an upregulation of the gene expressions of granzyme B, perforin and FasL. In the study, increased levels of these genes were detected in five out of five patients diagnosed with acute GVHD. There was a rather clear correlation between the increase and the onset of acute GVHD in four of these patients. The remaining patient, UPN 815, developed mild acute GVHD at the same time that they were diagnosed with a bacterial septicemia. Therefore, it was difficult to interpret the increase in gene expressions. Our findings are in agreement with those of Das et al, 16 who found that the gene expression levels of FasL increased in patients with acute GVHD after allogeneic SCT.
The clinical severity of acute GVHD did not correlate with the expression levels of the gene transcripts. However, our results show that patients with increasing gene expression levels during acute GVHD treatment have an increased risk of developing severe acute GVHD. Despite steroid treatment, UPN 803 and UPN 834 showed an upregulation of gene expressions and developed lifethreatening acute GVHD. Both patients died after SCT. In UPN 806, an upregulation of the gene expression was also detected during GVHD therapy, however, this patient only developed grade II acute GVHD. This could be of clinical value, since the method used in this study may identify patients with deteriorating acute GVHD, despite the administration of cortisone therapy. Patients with increasing immune transcript levels during GVHD treatment may benefit by early administration of ATG.
Several studies have provided evidence for the role of the three effector mechanisms (FasL, perforin/granzyme B and TNF-a) in specific GVHD target organ damage. These studies demonstrated that the Fas/FasL pathway was associated with cutaneous and hepatic GVHD, 32,33 while TNF-a was associated with cutaneous and intestinal GVHD. 33 The perforin/granzyme B pathway could not be related to specific GVHD target organ damage. 32 In this study, we could not show any correlation between specific immune transcript expression and specific target organ damage; however, only a few patients were included in this pilot study.
High expression levels of granzyme B, perforin and FasL may be induced by bacteremic infections as well as the onset of acute GVHD. Consequently, it was difficult to distinguish between patients suffering from a bacterial septicemia and acute GVHD. Current diagnostic techniques also have similar difficulties. 18, 34 However, it has been shown that increased serum levels of interleukin 6 (IL-6) Immune transcript levels after allogeneic SCT M Jaksch et al and C-reactive protein (CRP) can be correlated with severe bacterial infections, but not with acute GVHD. 35, 36 Therefore, with knowledge about these protein levels, the diagnostic problems may be evaded.
In our study, protein levels of granzyme B, sFasL and TNF-a in plasma were also assessed. However, the protein levels of TNF-a were impossible to evaluate since the majority of plasma samples contained protein concentrations under the level of sensitivity for the assay used. For granzyme B and sFasL, we showed a correlation of the protein levels and gene expression of the corresponding genes. However, the increases of protein levels were delayed, compared to the gene expression upregulation, which is to be expected. Owing to this delay, measurements of gene expression rather than protein levels may be more suitable in order to predict acute GVHD as early as possible. Also, for cytokine analysis, increased levels are not necessarily associated with acute GVHD. High levels of TNF-a, for example, are not only associated with acute GVHD but also with other transplant-related complications, including infections and veno-occlusive disease. 37 More studies are needed however to determine the usefulness of the assessment of plasma protein levels of granzyme B, sFasL and TNF-a.
In conclusion, using gene-specific constructs of competitor DNA, the quantitative RT-PCR of granzyme B, perforin and FasL, together with the analysis of soluble IL-2 receptors, 38 may serve as a guide to the clinician in diagnosing acute GVHD and monitoring treatment. This technique offers a less invasive approach than core biopsies, however, it remains to be determined whether or not the same reliability can be achieved. Additional prospective follow-up studies, with a greater number of patients and more frequent monitoring, is required to determine the usefulness of the measurements of granzyme B, perforin and FasL gene expression levels as an approach for monitoring the onset of acute GVHD and follow-up therapy.
